Drug Trial Radar · NCT05868226
PRE-ISPY Phase I/II Oncology Platform Program
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Feb 15, 2023
Primary completion
Dec 30, 2030
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- QuantumLeap Healthcare CollaborativeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ALX Oncology Inc.; Pfizer; Jazz Pharmaceuticals; TransCode Therapeutics
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with curative intent. The overall goal is moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 Trial (NCT01042379) and/or other oncology solid tumor trial in a timely manner.
Conditions
- HER2-positive Breast Cancer
- Metastatic Cancer
- Metastatic Breast Cancer
- Metastatic
- HER2-positive Metastatic Breast Cancer
- HER2 Mutation-Related Tumors
- HER-2 Protein Overexpression
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- HR Positive
- Hormone Receptor-positive Breast Cancer
- Estrogen Receptor Positive Tumor
- Progesterone Receptor-positive Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
- Solid Tumor
- Solid Tumor, Adult
- Solid Carcinoma
- HER2 Low Breast Cancer
- HER2 Low Breast Carcinoma
- ER Positive Breast Cancer
- PR-positive Breast Cancer
- Minimal Residual Disease
- Colo-rectal Cancer
- Colon Cancer
- Rectal Cancer
- ctDNA Monitoring
- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms
- Neoplasm, Residual
- Adenocarcinoma of Colon
- Adenocarcinoma
Interventions
ALX148Drug
Starting dose Dose Level 1 30mg/kg IV Q3W; Dose Level Minus 1 20 mg/kg IV Q3W (if needed); Dose Level 2 45 mg/kg IV Q3W;
Fam-Trastuzumab Deruxtecan-NxkiDrug
5.4 mg/kg IV Q3W; allowed to dose reduce after DLT observation period
ZanidatamabDrug
20 mg/kg IV Q2W on Day 1 and Day 15 of each 28 day cycle
TucatinibDrug
Dose Level 1: 300 mg PO BID daily; Dose Leve Minus 1: 250 mg PO BID daily
TTX-MC138Drug
4.8 mg/kg Q4W IV on Day 1 for up to 12 cycles as interception therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events related to the treatmentTime frame: Start of treatment to 30 days post treatment (estimated 12 -18 months)
- For Phase Ib Part 1 study design: Incidence of Dose Limiting Toxicities (DLTs) at each dose levelTime frame: DLT observation period: Start of treatment to end of Cycle 1
- For select drug arms, Maximum Tolerated Dose (MTD)Time frame: Start of treatment to the date of last participant at end of DLT observation period at highest dose level (estimated 6 months)
- For Phase Ib Part 1 drug arms, Recommended Phase 2 Dose (RP2D)Time frame: Start of treatment to the date of last participant at highest dose level (estimated 6 months)
- Overall Response Rate (ORR)Time frame: Start of treatment to 12 months
- Duration of Response (DOR)Time frame: Start of treatment to 12 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Birmingham, Alabama · Recruiting
Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona · Not yet recruiting
University of Colorado Cancer Center
Aurora, Colorado · Active not recruiting
Moffitt Cancer Center
Tampa, Florida · Active not recruiting
The University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois · Recruiting
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois · Recruiting
UChicago Medicine Orland Park
Orland Park, Illinois · Recruiting
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota · Recruiting
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.